SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is a biopharma company making medicines for people with severe rare diseases and ...

On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...

Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following ...

SpringWorks Therapeutics Inc ... for SpringWorks is the ongoing merger and acquisition discussions with Merck KGaA. Analysts view this potential acquisition as strategically sound for several ...

A potential acquisition of SpringWorks Therapeutics by Merck KGaA could bring significant benefits to both companies and potentially create substantial value for shareholders: 1. Enhanced resources: ...

SpringWorks Therapeutics, Inc. (NASDAQ ... is up significantly so far in 2025 due to advanced acquisition talks with Merck KGaA. Furthermore, on February 11, 2025, the FDA approved GOMEKLI ...